Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II safety and reactogenicity study of GSK3003891A RSV vaccine in healthy non-pregnant women
2015-005742-58Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus disease (RSV), sponsored by GSK. Primary endpoint: Haematological and biochemical laboratory abnormalities. Started Feb 2016; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2015-005742-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005742-58.